SCF-PCR THERAPEUTIC TREATMENT STRATEGY — ALS | FDA-ALIGNED DRUG MAPPING + SCF-PCR BRAID DOSING SEQUENCE + SYNERGISTIC AUGMENTATION

Program Code: SCF-ALS-PCR-MAP-0001

Framework: SCF-PCR Braid × FDA Translational Integration × Synergistic Compatibility Principles

SECTION 1 — OBJECTIVE

To map the SCF-PCR therapeutic architecture onto:

FDA-approved ALS drugs
Late-stage / pre-approved pipeline agents
Mechanistically aligned adjunct therapies

With:

Dosing sequence (PCR braid timing)
Synergistic augmentation logic (1+1⇒3 framework)

SECTION 2 — DRUG CLASSIFICATION (SOC + PIPELINE)

2.1 FDA-APPROVED (SOC)

Drug	Mechanism	SCF Role
Riluzole	Glutamate inhibition	Excitotoxic suppression
Edaravone	Free radical scavenger	Redox stabilizer
AMX0035 (PB-TURSO)	Mitochondrial + ER stress modulation	Bioenergetic stabilizer

2.2 PRE-APPROVED / PIPELINE (ADVANCED)

Drug	Mechanism	SCF Role
Tofersen	ASO targeting SOD1	Gene/RNA suppression
BIIB078	ASO targeting C9orf72	RNA toxicity suppression
Masitinib	Tyrosine kinase inhibitor	Neuroinflammation control
CNM-Au8	Nanocatalyst (bioenergetics)	Mitochondrial enhancer
NurOwn (MSC-NTF)	Stem cell therapy	Neuroregeneration

SECTION 3 — SCF-PCR BRAID MAPPING (DRUG ALIGNMENT)

3.1 PREVENTATIVE (P) — UPSTREAM STABILIZATION

Drug	Mechanism	Justification
BIIB078 (ASO)	Suppresses C9orf72 RNA repeats	Directly blocks RNA toxicity (root driver)
Edaravone	ROS scavenging	Prevents oxidative DNA/RNA damage
CNM-Au8	Enhances ATP production	Stabilizes early mitochondrial dysfunction

SCF Logic

Targets T1–T2 window (pre-symptomatic → prodromal)
Prevents RNA → protein misfolding cascade initiation

3.2 CURATIVE (C) — CORE PATHOLOGY ELIMINATION

Drug	Mechanism	Justification
Tofersen	SOD1 suppression	Eliminates mutation-driven toxicity
Riluzole	Glutamate inhibition	Reduces excitotoxic neuron death
Masitinib	Microglial modulation	Suppresses inflammatory amplification
AMX0035	Mitochondrial + ER protection	Restores proteostasis + energy

SCF Logic

Targets T2–T4 window
Interrupts protein misfolding + mitochondrial collapse + immune amplification

3.3 RESTORATIVE (R) — SYSTEM RECONSTRUCTION

Drug	Mechanism	Justification
NurOwn (MSC-NTF)	Neurotrophic factor delivery	Promotes neuron survival/regeneration
CNM-Au8	Metabolic restoration	Sustains energy recovery
Omega-3 derivatives (adjunct)	Synaptic repair	Membrane restoration

SCF Logic

Targets T4–T6 window
Rebuilds ECM–neuron–synaptic integrity

SECTION 4 — SCF-PCR BRAID DOSING SEQUENCE

4.1 Temporal Sequencing Model

Phase	Time	Dominant Module	Drug Stack
Phase 1 (Initiation)	T1–T2	Preventative	BIIB078 + Edaravone + CNM-Au8
Phase 2 (Early Disease)	T2–T3	P + C overlap	+ Tofersen + Riluzole
Phase 3 (Progression)	T3–T4	Curative dominant	+ Masitinib + AMX0035
Phase 4 (Advanced)	T4–T5	C + R overlap	+ NurOwn
Phase 5 (Late)	T5–T6	Restorative	NurOwn + metabolic support

4.2 Chronopharmacologic Optimization

Morning: Mitochondrial + metabolic agents (CNM-Au8, AMX0035)
Midday: RNA/gene therapies (ASOs)
Evening: Anti-inflammatory + antioxidant (Masitinib, Edaravone)

SECTION 5 — SYNERGISTIC AUGMENTATION (SCF 1+1⇒3 FRAMEWORK)

5.1 CORE SYNERGY PAIRS

Pair 1: BIIB078 + Edaravone

Component	Role
BIIB078	Eliminates RNA toxicity
Edaravone	Prevents ROS-induced RNA damage

Augmentation Logic:

RNA suppression + oxidative protection → enhanced RNA stability

Synergy Outcome: Prevents re-initiation of toxic transcripts

Pair 2: Tofersen + AMX0035

Component	Role
Tofersen	Reduces toxic SOD1
AMX0035	Protects mitochondria + ER

Augmentation Logic:

Remove toxic protein + stabilize cell environment → enhanced neuronal survival

Synergy Outcome: Reduced apoptosis + restored proteostasis

Pair 3: Masitinib + Riluzole

Component	Role
Masitinib	Immune suppression
Riluzole	Excitotoxicity reduction

Augmentation Logic:

Reduce inflammation + excitotoxicity → dual protection of neurons

Synergy Outcome: Slower degeneration

Pair 4: CNM-Au8 + NurOwn

Component	Role
CNM-Au8	Energy restoration
NurOwn	Neuroregeneration

Augmentation Logic:

Energy supply + regenerative signaling → enhanced neuronal repair capacity

Synergy Outcome: Increased functional recovery potential

SECTION 6 — FULL SYNERGY STACK (FIBONACCI MODEL)

Role	Drug	Function
F1	ASO (BIIB078 / Tofersen)	Root cause elimination
F2	Edaravone	Safety harmonizer
F3	AMX0035 / CNM-Au8	Metabolic stabilizer
F5	Riluzole	Excitotoxic control
F8–F13	Masitinib + NurOwn + adjuncts	System-wide support

SECTION 7 — SAFETY & INTERACTION MANAGEMENT

Risk	Mitigation
ASO immune response	Controlled dosing, intrathecal delivery
Polytherapy burden	SCF synergy reduces dose requirements
Hepatic load (riluzole)	Monitoring + dose adjustment
Immune suppression (masitinib)	Stratified patient selection

SECTION 8 — EXPECTED SYNERGISTIC OUTCOME

Domain	Outcome
RNA toxicity	Suppressed
Protein aggregation	Reduced
Mitochondrial function	Restored
Neuroinflammation	Controlled
Neuroregeneration	Activated

SECTION 9 — FINAL SCF SYNTHESIS

Key Insight

SOC drugs alone = linear, limited efficacy
SCF-PCR braid = nonlinear, synergistic multi-axis correction

SCF FINAL CONCLUSION

The integration of FDA-approved and pipeline therapies into the SCF-PCR braid:

Converts fragmented therapies → unified system
Enables multi-stage disease interception
Achieves synergistic amplification beyond additive effects

Therapeutic Paradigm Shift

From: Symptom management

To: Multi-omic disease reconstruction

MASTER INDEX REGISTRY CODE

SCF-ALS-PCR-MAP-0001-T